Skip to content
OpenCapital
Get started

Evommune EVMN Hemp Derived Products — Revenue

Other product segments

Nutraceuticalsupplements
$1.64M+7.8%

Similar metrics at other companies

Cronos Group logo
CRONCannabis flower — Net revenue
$33.73M+44.5%
Cronos Group logo
CRONCannabis extracts — Net revenue
$11.46M+33.1%
GigaCloud Technology logo
GCTProducts — Revenue
$242.95M+36.6%
AMP
AMPHPharmaceutical Products — Revenue
$171.17M+0.4%
Innovative Industrial Properties, Inc. logo
IIPRCannabis Portfolio Segment: — Revenue
$69M-3.8%
HWK
HWKNAgricultural — Revenue
$15.07M+19.7%

Other financials

Income statement

See full
Revenue$1.6M+3.5%
Gross profit$961.1K+10.9%
Operating income-$682.8K-2,027%
Net income-$7.0M-5,414%
EPS (diluted)-$0.36-1,700%

Balance sheet

See full
Cash & equivalents$1.1M+401%
Total debt$2.0M—
Total equity-$4.5M-3,048%
Total assets$7.2M—

Cash flow

See full
Operating cash flow-$424.6K-341%
CapEx$1.0-99.8%
Free cash flow-$2.7M-4,996%

Valuation

See full
Market cap$848.59M+39.5%
Enterprise value$849.52M—
P/S127.3×—

Profitability

See full
Gross margin53.7%—
Operating margin-30.7%—
Net margin-90.1%—

Returns & leverage

See full
Return on equity275.7%—
Debt / equity1.4×—
Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's hemp derived products — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evommune 's hemp derived products — revenue?
Evommune (EVMN) reported hemp derived products — revenue of $6.27K in Q1 2026.
How has Evommune 's hemp derived products — revenue changed year-over-year?
Evommune 's hemp derived products — revenue decreased by 91.0% year-over-year, from $70K to $6.27K.
What does hemp derived products — revenue mean?
This metric represents the total gross revenue generated from the sale of products derived from hemp within the specified reporting period. It serves as a key indicator of market demand and commercial traction for the company's non-core or diversified product offerings. Tracking this revenue stream helps investors evaluate the performance and growth trajectory of the company's specific business segment outside of its primary clinical-stage biotechnology operations.